Treatment and biology of pediatric acute lymphoblastic leukemia
Top Cited Papers
Open Access
- 21 January 2018
- journal article
- review article
- Published by Wiley in Pediatrics International
- Vol. 60 (1), 4-12
- https://doi.org/10.1111/ped.13457
Abstract
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. In the past ALL was intractable but now the survival probability is as high as 80-90%. Improved supportive care, treatment stratification based on relapse risk, biological features of leukemic cells, and optimization of treatment regimens by nationwide and international collaboration have contributed to this dramatic improvement. While including traditional risk factors (e.g., age and leukocyte count at diagnosis), the treatment has been modified based on biological characteristics (aneuploidy and translocation) and treatment response (assessed by minimal residual disease). Treatment for pediatric ALL typically consists of induction therapy with steroids, vincristine, and asparaginase with or without anthracycline, followed by multiagent consolidation including high-dose methotrexate and re-induction therapy. After consolidation, less intensive maintenance therapy is required for 1-2 years to maintain event free survival of the patients. Recently, advanced genomic analysis technology identified novel sentinel genomic alterations which may provide more precise stratification or therapeutic targets. Moreover, in the last decade we have seen that germline variations are similarly important contributors to understanding the etiology and sensitivity of ALL to treatment. A more individualized approach based on genomic features (somatic and germline) and treatment response, the introduction of newly developed agents such as molecular targeted drugs or immunotherapy, and social supports including long-term follow up are required for further improvement.Keywords
Funding Information
- Japan Agency for Medical Research and Development (17ck0106334)
- National Center for Child Health and Development (28-5)
This publication has 83 references indexed in Scilit:
- Tyrosine Kinase Inhibitor Therapy Induces Remission in a Patient With Refractory EBF1-PDGFRB–Positive Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2013
- Acute lymphoblastic leukaemiaThe Lancet, 2013
- Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup studyThe Lancet Oncology, 2012
- ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapyLeukemia, 2011
- Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemiaNature Genetics, 2009
- Treating Childhood Acute Lymphoblastic Leukemia without Cranial IrradiationNew England Journal of Medicine, 2009
- Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1Leukemia, 2009
- A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification studyThe Lancet Oncology, 2009
- Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarrayBlood, 2008
- Outcome of treatment in children with hypodiploid acute lymphoblastic leukemiaBlood, 2007